Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxane · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Oral Taxane | DRUG | - |
Inclusion Criteria: * Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions. * ECOG Performance Status 0-2 Exclusion Criteria: * Inability to swallow capsules * Recent significant cardiovascular disease * Women who are pregnant or breastf...
Top 20 of 84 competitors
Taxane is an investigational small molecule being studied for the treatment of Non-small Cell Lung Cancer. It is currently in Phase 1 clinical development. The drug is being evaluated in combination with pemetrexed (Alimta) for patients with recurrent Non-small Cell Lung Cancer.
Taxane is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Non-small Cell Lung Cancer.
Taxane is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate its use in combination with pemetrexed for recurrent Non-small Cell Lung Cancer.
Taxane has been studied in one clinical trial with the identifier NCT00103831. This Phase 1 trial, titled 'Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer,' was completed and conducted in the United States and Canada.
No, Taxane is a distinct investigational drug being developed by Bristol-Myers Squibb. While it belongs to the taxane class of chemotherapy agents, it is not the same as paclitaxel or docetaxel. The drug is being studied specifically for Non-small Cell Lung Cancer.